Labopharm Once-Daily Tramadol NDA Planned For Second Half 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will conduct an additional pivotal trial in support of moderate to moderately-severe pain indication following discussions with FDA. Biovail’s once-daily tramadol Ralivia ER is pending at FDA with a PDUFA date of Oct. 31.
You may also be interested in...
Biovail’s Tramadol ER Approved Without Additional Clinical Studies
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.
Biovail’s Tramadol ER Approved Without Additional Clinical Studies
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.
Biovail Ralivia ER “Approvable” At FDA Pending Further Clinical Information
The company believes that the Ralivia ER NDA has sufficient data to fulfill FDA’s request. Biovail is seeking a U.S. marketing partner for the long-acting opioid analgesic.